 influenc autolog lymphokine-activ killer cell infus toxic antitumor effect repetit cycl patient refractori malign protocol addit ex vivo-activ autolog lymphokine-activ killer lak cell toler regimen weekli cycl human recombin continu infus days/week sixteen patient induct month therapi partial respons stabl diseas progress diseas patient clinic toxic complet induct month therapi patient therapi signific clinic toxic decreas perform statu gain catheter-rel thrombos infecti complic fever hypotens dyspnea hypoxemia oxygen addit lak cell infus regimen notic chang antitumor respons rate sever toxic